The first targeted commercial application of SmartTab™ is Crohn's disease. Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can eventually lead to abdominal pain, fatigue, chronic diarrhea, weight loss, and malnutrition.

A significant problem in the United States with an estimate of 1.3% of adults (three million) reportedly being diagnosed. The mean hospitalization cost of Crohn's disease in the United States is over $11,000 which implies that over $34 billion is spent each year in treating the disease.


Medications used to treat inflammation of the colon are not able to reach the colon intact, they often don’t have proper dosages and most times, they are not released at the most beneficial times or location. By the time the medication travels through the upper GI tract, the medication has a difficult time making its way down to the colon where it is most needed for effective performance.

With our targeted delivery system, we would be able to have our SmartTab™ travel to the colon intact.
— Robert Niichel, Founder and CEO

Deriving satisfaction for the money being paid for hospitalization in order to enjoy good health within the shortest period of time is the goal of every patient and this can only be achieved if the medications are able to perform effectively at the right site in the body. Crohn’s disease patients can significantly benefit from our technology by having a targeted delivery system to the colon.


The SmartTab™ will travel to the colon intact and could target a very precise location in the colon and then trigger the release of the active ingredients from a smartwatch, smartphone, or a PC in a clinical setting.

Not only will this delivery system provide targeted treatment of the colon, but it will also significantly reduce any types of side effects that are associated with current medicines in the market. This will lead to improved patient outcomes, as well as reduce healthcare costs in the Crohn's industry.

Inoel Mirandabenefits